Company Filing History:
Years Active: 2019-2020
Title: Florie Borel: Innovator in Transgenic Research
Introduction
Florie Borel is a notable inventor based in Saint Martin, France. She has made significant contributions to the field of transgenic research, particularly in the study of alpha-one antitrypsin deficiency. With a total of 2 patents, her work has implications for understanding and treating genetic disorders.
Latest Patents
Florie Borel's latest patents include a method of using a transgenic mouse with alpha-one antitrypsin (ATT) deficiency to screen compounds. This patent describes transgenic non-human animals, specifically rodents, that possess genomic mutations which inactivate all of the serpin1A genes, resulting in the absence of functional serpinA1 genes. Consequently, these animals do not express hepatic or circulatory AAT protein. Additionally, her patent provides cells and tissues derived from these transgenic mice. Another significant patent is the mouse model of alpha-one antitrypsin (AAT) deficiency, which shares similar characteristics and implications as her previous work.
Career Highlights
Florie Borel is affiliated with the University of Massachusetts, where she continues her research and innovation in the field of genetics. Her work has garnered attention for its potential applications in medical research and therapeutic development.
Collaborations
Florie collaborates with Christian Mueller, who is also involved in research related to transgenic models and genetic disorders.
Conclusion
Florie Borel's innovative work in transgenic research highlights her contributions to understanding genetic deficiencies and developing potential therapeutic approaches. Her patents reflect a commitment to advancing scientific knowledge and improving health outcomes.